Brokerages expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to announce $6.69 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Pieris Pharmaceuticals’ earnings. The lowest sales estimate is $4.50 million and the highest is $8.80 million. Pieris Pharmaceuticals reported sales of $18.15 million in the same quarter last year, which indicates a negative year-over-year growth rate of 63.1%. The business is scheduled to issue its next earnings results on Friday, March 8th.
On average, analysts expect that Pieris Pharmaceuticals will report full year sales of $30.66 million for the current fiscal year, with estimates ranging from $28.70 million to $33.00 million. For the next fiscal year, analysts expect that the company will report sales of $22.74 million, with estimates ranging from $12.00 million to $31.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%. The company had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.16 million.
In other Pieris Pharmaceuticals news, Director Christopher P. Kiritsy purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The stock was acquired at an average cost of $5.11 per share, with a total value of $25,550.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $51,100. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.07% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio bought a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $110,000. Marshall Wace LLP bought a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $118,000. Bowling Portfolio Management LLC bought a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $156,000. California Public Employees Retirement System bought a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $179,000. Finally, DRW Securities LLC increased its stake in Pieris Pharmaceuticals by 50.0% in the second quarter. DRW Securities LLC now owns 45,000 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 15,000 shares in the last quarter. 65.36% of the stock is owned by institutional investors and hedge funds.
Shares of PIRS stock remained flat at $$3.51 during trading hours on Wednesday. 428,334 shares of the stock were exchanged, compared to its average volume of 569,235. Pieris Pharmaceuticals has a 12 month low of $3.04 and a 12 month high of $9.75. The firm has a market capitalization of $190.07 million, a price-to-earnings ratio of -8.78 and a beta of 1.88.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
See Also: What is a Futures Contract?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.